11/24
07:00 am
mcrb
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Medium
Report
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
11/18
01:20 pm
mcrb
Seres Therapeutics (NASDAQ:MCRB) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
High
Report
Seres Therapeutics (NASDAQ:MCRB) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
11/5
07:00 am
mcrb
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Medium
Report
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
10/30
07:00 am
mcrb
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
Medium
Report
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
10/29
07:00 am
mcrb
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
Low
Report
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
10/14
07:53 am
mcrb
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant [Yahoo! Finance]
Low
Report
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant [Yahoo! Finance]
10/14
07:00 am
mcrb
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Low
Report
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant
9/24
08:06 am
mcrb
Seres Therapeutics (NASDAQ:MCRB) had its price target raised by analysts at Canaccord Genuity Group Inc. from $14.00 to $22.00. They now have a "buy" rating on the stock.
High
Report
Seres Therapeutics (NASDAQ:MCRB) had its price target raised by analysts at Canaccord Genuity Group Inc. from $14.00 to $22.00. They now have a "buy" rating on the stock.
9/23
07:52 am
mcrb
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway [Yahoo! Finance]
Low
Report
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway [Yahoo! Finance]
9/23
07:00 am
mcrb
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
Medium
Report
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
9/22
12:16 pm
mcrb
Factbox-More companies adopt co-CEO structure [Yahoo! Finance Canada]
Low
Report
Factbox-More companies adopt co-CEO structure [Yahoo! Finance Canada]
9/22
12:13 pm
mcrb
Factbox-More companies adopt co-CEO structure [Yahoo! Finance]
Low
Report
Factbox-More companies adopt co-CEO structure [Yahoo! Finance]
9/8
04:54 am
mcrb
Human Microbiome Global Forecast Report 2025 | Market Set to Surge, Reaching USD 7.09 Billion by 2031 Driven by Personalized Medicine Demand [Yahoo! Finance]
High
Report
Human Microbiome Global Forecast Report 2025 | Market Set to Surge, Reaching USD 7.09 Billion by 2031 Driven by Personalized Medicine Demand [Yahoo! Finance]